Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody

PHASE3CompletedINTERVENTIONAL
Enrollment

226

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

November 30, 2009

Study Completion Date

December 31, 2009

Conditions
Renal Cell CarcinomaKidney Cancer
Interventions
DRUG

124-Iodine-cG250 (124I-cG250)

i.v. and PET/CT scan 4+/-2 days after administration

PROCEDURE

CT

contrast enhanced CT scan

Trial Locations (14)

10021

Memorial Sloan-Kettering Cancer Center, New York

27599

UNC School of Medicine-Chapel Hill, Chapel Hill

27711

Duke University Medical Center, Durham

33612

H. Lee Moffitt Cancer Center & Research Center, Tampa

43210

Ohio State University, Columbus

44195

Cleveland Clinic Foundation, Cleveland

89135

Nevada Cancer Institute, Las Vegas

94305

Stanford University Medical Center, Stanford

90095-1721

David Geffen School of Medicine, UCLA, Los Angeles

01805

Lahey Clinic, Burlington

48109-0330

University of Michigan, Ann Arbor

19104-4283

Fox Chase Cancer Center, Philadelphia

Hospital of the University of Pennsylvania, Philadelphia

77030-4009

MD Anderson, Houston

Sponsors
All Listed Sponsors
lead

Heidelberg Pharma AG

INDUSTRY